Literature DB >> 30225787

Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.

A M Buchanan-Hughes1, M Buti2,3, K Hanman4, B Langford4, M Wright5, L A Eddowes4.   

Abstract

PURPOSE: Chronic hepatitis C infection and its treatment can considerably affect patients' health-related quality-of-life (HRQoL). This study aimed to identify and summarise the current evidence base for health state utility values (HSUVs) in patients with chronic hepatitis C infection, generated using the EuroQol 5-dimensions (EQ-5D) questionnaire.
METHODS: MEDLINE, Embase, the Cochrane Library and EconLit were searched from database inception through 31 August 2017. Eligible studies reported HSUVs elicited using the EQ-5D questionnaire in adults with chronic hepatitis C infection. Study quality and risk of bias were assessed.
RESULTS: Of 1480 records identified, 26 studies were included. The most commonly defined health states described different stages of chronic hepatitis C infection and specific liver-related disease states, including METAVIR score, compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Patients with higher METAVIR scores tended to have lower EQ-5D scores compared to patients with lower METAVIR scores. Patients that achieved sustained virologic responses tended to have higher EQ-5D scores compared to those that did not. A meta-analysis conducted on three studies confirmed that patients with decompensated cirrhosis have significantly lower HSUVs than patients with compensated cirrhosis [mean difference - 0.11 (95% CI - 0.19 to - 0.04)], implying worse HRQoL. However, there was not sufficient evidence to compare how different treatments for chronic hepatitis C infection affect EQ-5D scores.
CONCLUSIONS: This study provides a summary of EQ-5D HSUVs for patients with chronic hepatitis C infection, and demonstrates that clinically important disease stages associated with treatment decisions are associated with differences in HRQoL.

Entities:  

Keywords:  EQ-5D; HCV; Hepatitis C; QoL; Quality of life; Utility

Mesh:

Year:  2018        PMID: 30225787     DOI: 10.1007/s11136-018-1992-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  10 in total

1.  Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.

Authors:  Ru Han; Clément François; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

2.  Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients.

Authors:  Bushra Ali; Ikram Ul Haq Raja; Asad Choudhry; Arif Amir Nawaz
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

3.  Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.

Authors:  Jennifer Uyei; Tamar H Taddei; David E Kaplan; Michael Chapko; Elizabeth R Stevens; R Scott Braithwaite
Journal:  PLoS One       Date:  2019-08-26       Impact factor: 3.240

4.  Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of life.

Authors:  Carolina Rosadas; Tatiane Assone; Marina Yamashita; Adine Adonis; Marzia Puccioni-Sohler; Marisa Santos; Arthur Paiva; Jorge Casseb; Augusto C P Oliveira; Graham P Taylor
Journal:  PLoS Negl Trop Dis       Date:  2020-10-16

5.  Health-Related Quality of Life Among Liver Disorder Patients in Northern India.

Authors:  Yashika Chugh; Swati Katoch; Deepshikha Sharma; Pankaj Bahuguna; Ajay Duseja; Manmeet Kaur; Radha Krishan Dhiman; Shankar Prinja
Journal:  Indian J Community Med       Date:  2022-03-16

6.  Health-Related Quality of Life and Its Contributors According to a Preference-Based Generic Instrument in Cirrhosis.

Authors:  Yangyang Hui; Nan Li; Zihan Yu; Chaoqun Li; Xiaoyu Wang; Yifan Li; Mingyu Sun; Wanting Yang; Gaoyue Guo; Xiaofei Fan; Lin Lin; Binxin Cui; Xin Chen; Bangmao Wang; Jie Zhang; Chao Sun
Journal:  Hepatol Commun       Date:  2021-09-24

7.  Value appropriation in hepatitis C.

Authors:  Peter Lindgren; Sofia Löfvendahl; Gunnar Brådvik; Ola Weiland; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2021-12-02

8.  The effect of a pay-for-performance program on health-related quality of life for patients with hepatitis in Taiwan.

Authors:  Wei-Chih Su; Tsung-Tai Chen; Sien-Sing Yang; Ling-Na Shih; Chih-Kuang Liu; Chia-Chi Wang; Chien-Hsien Wu
Journal:  Health Qual Life Outcomes       Date:  2022-09-05       Impact factor: 3.077

9.  Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.

Authors:  Hui Jun Zhou; Jing Cao; Hui Shi; Nasheen Naidoo; Sherehe Semba; Pei Wang; Yi Fan Fan; Shui Cheng Zhu
Journal:  Front Public Health       Date:  2021-12-09

10.  Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.

Authors:  Akio Miyasaka; Yuichi Yoshida; Akiko Suzuki; Yasuhiro Takikawa
Journal:  Qual Life Res       Date:  2021-05-19       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.